 Jason Farrar
Concepts (243)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 15 | 2024 | 185 | 3.310 |
Why?
| | Anemia, Diamond-Blackfan | 13 | 2024 | 13 | 2.880 |
Why?
| | Mutation | 15 | 2023 | 1294 | 1.800 |
Why?
| | Ribosomal Proteins | 9 | 2021 | 25 | 1.570 |
Why?
| | Gene Expression Profiling | 7 | 2023 | 1037 | 0.860 |
Why?
| | Rhabdomyosarcoma, Alveolar | 1 | 2021 | 8 | 0.790 |
Why?
| | Li-Fraumeni Syndrome | 1 | 2021 | 13 | 0.790 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2021 | 203 | 0.700 |
Why?
| | RNA Processing, Post-Transcriptional | 3 | 2014 | 24 | 0.580 |
Why?
| | GATA1 Transcription Factor | 2 | 2017 | 7 | 0.510 |
Why?
| | Oncogene Proteins, Fusion | 4 | 2024 | 58 | 0.500 |
Why?
| | RNA, Ribosomal | 1 | 2014 | 20 | 0.480 |
Why?
| | RNA Precursors | 1 | 2014 | 9 | 0.480 |
Why?
| | Codon, Initiator | 1 | 2014 | 9 | 0.470 |
Why?
| | Meningitis, Cryptococcal | 2 | 2010 | 10 | 0.460 |
Why?
| | Child, Preschool | 16 | 2021 | 3883 | 0.460 |
Why?
| | Point Mutation | 1 | 2014 | 65 | 0.460 |
Why?
| | Humans | 44 | 2024 | 50208 | 0.420 |
Why?
| | Breast Neoplasms | 1 | 2021 | 1179 | 0.410 |
Why?
| | Prognosis | 6 | 2024 | 1954 | 0.400 |
Why?
| | Cryptococcus neoformans | 2 | 2010 | 27 | 0.390 |
Why?
| | Infant | 12 | 2021 | 3563 | 0.390 |
Why?
| | Amplified Fragment Length Polymorphism Analysis | 1 | 2010 | 3 | 0.380 |
Why?
| | Mycological Typing Techniques | 1 | 2010 | 3 | 0.380 |
Why?
| | Child | 20 | 2024 | 6851 | 0.370 |
Why?
| | DNA, Fungal | 1 | 2010 | 41 | 0.370 |
Why?
| | Gene Deletion | 1 | 2011 | 270 | 0.360 |
Why?
| | DNA Methylation | 6 | 2023 | 550 | 0.290 |
Why?
| | Female | 18 | 2021 | 26635 | 0.280 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2013 | 485 | 0.260 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2011 | 411 | 0.250 |
Why?
| | Adolescent | 11 | 2022 | 6390 | 0.240 |
Why?
| | Hemophilia A | 1 | 2024 | 25 | 0.230 |
Why?
| | Young Adult | 10 | 2024 | 3981 | 0.220 |
Why?
| | Male | 17 | 2020 | 25399 | 0.220 |
Why?
| | Gene Rearrangement | 1 | 2024 | 74 | 0.220 |
Why?
| | Cell Cycle Proteins | 2 | 2021 | 166 | 0.220 |
Why?
| | Consensus | 1 | 2024 | 150 | 0.220 |
Why?
| | Osteosarcoma | 1 | 2023 | 47 | 0.220 |
Why?
| | Dengue | 2 | 2013 | 4 | 0.210 |
Why?
| | Azacitidine | 2 | 2023 | 34 | 0.210 |
Why?
| | Chromosome Aberrations | 3 | 2017 | 297 | 0.200 |
Why?
| | Leukemia, Myelomonocytic, Juvenile | 1 | 2022 | 17 | 0.200 |
Why?
| | Bone Neoplasms | 1 | 2023 | 183 | 0.190 |
Why?
| | Co-Repressor Proteins | 1 | 2021 | 20 | 0.190 |
Why?
| | Neoplasms, Second Primary | 1 | 2022 | 78 | 0.190 |
Why?
| | Gene Regulatory Networks | 1 | 2021 | 107 | 0.190 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2021 | 40 | 0.190 |
Why?
| | B-Lymphocytes | 1 | 2021 | 170 | 0.180 |
Why?
| | Chromatin | 1 | 2021 | 152 | 0.170 |
Why?
| | Leucine | 1 | 2020 | 117 | 0.170 |
Why?
| | Blood Transfusion | 1 | 2020 | 126 | 0.170 |
Why?
| | Vietnam | 4 | 2013 | 22 | 0.170 |
Why?
| | MicroRNAs | 2 | 2021 | 355 | 0.170 |
Why?
| | Recurrence | 2 | 2022 | 662 | 0.160 |
Why?
| | Ribosomes | 2 | 2009 | 36 | 0.160 |
Why?
| | Research Report | 1 | 2018 | 16 | 0.160 |
Why?
| | DNA-Binding Proteins | 1 | 2021 | 428 | 0.150 |
Why?
| | Induction Chemotherapy | 1 | 2017 | 60 | 0.150 |
Why?
| | Ribosome Subunits, Large, Eukaryotic | 2 | 2014 | 2 | 0.140 |
Why?
| | Agammaglobulinemia | 1 | 1996 | 9 | 0.140 |
Why?
| | X Chromosome | 1 | 1996 | 13 | 0.140 |
Why?
| | Genome, Human | 2 | 2021 | 111 | 0.140 |
Why?
| | Phenotype | 3 | 2021 | 733 | 0.140 |
Why?
| | HIV Infections | 2 | 2010 | 357 | 0.140 |
Why?
| | Receptors, Colony-Stimulating Factor | 1 | 2016 | 1 | 0.140 |
Why?
| | CCAAT-Enhancer-Binding Proteins | 1 | 2016 | 14 | 0.140 |
Why?
| | Cell Proliferation | 4 | 2021 | 1013 | 0.130 |
Why?
| | Neutropenia | 1 | 1996 | 115 | 0.130 |
Why?
| | Immunologic Factors | 2 | 2013 | 114 | 0.130 |
Why?
| | Treatment Outcome | 3 | 2023 | 5155 | 0.130 |
Why?
| | Genotype | 3 | 2013 | 534 | 0.130 |
Why?
| | DNA Copy Number Variations | 1 | 2016 | 110 | 0.130 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 595 | 0.130 |
Why?
| | Influenza A Virus, H5N1 Subtype | 1 | 2015 | 1 | 0.130 |
Why?
| | Registries | 1 | 2018 | 522 | 0.130 |
Why?
| | Ribosome Subunits, Small, Eukaryotic | 1 | 2014 | 2 | 0.120 |
Why?
| | K562 Cells | 1 | 2014 | 42 | 0.120 |
Why?
| | Transcription Factors | 3 | 2024 | 564 | 0.120 |
Why?
| | Chromosome Mapping | 3 | 2011 | 156 | 0.120 |
Why?
| | Leukemia, Myeloid | 1 | 2014 | 43 | 0.120 |
Why?
| | Influenza, Human | 1 | 2015 | 84 | 0.120 |
Why?
| | Molecular Epidemiology | 2 | 2010 | 39 | 0.120 |
Why?
| | Anemia, Macrocytic | 1 | 2013 | 2 | 0.110 |
Why?
| | Adult | 8 | 2022 | 13324 | 0.110 |
Why?
| | Prednisolone | 1 | 2013 | 55 | 0.110 |
Why?
| | Cytogenetic Analysis | 1 | 2013 | 82 | 0.110 |
Why?
| | Cluster Analysis | 2 | 2010 | 235 | 0.110 |
Why?
| | Base Sequence | 3 | 2010 | 644 | 0.110 |
Why?
| | Infant, Newborn | 3 | 2019 | 2766 | 0.110 |
Why?
| | RNA, Messenger | 4 | 2021 | 1108 | 0.100 |
Why?
| | Heart Defects, Congenital | 1 | 2018 | 585 | 0.100 |
Why?
| | Genomics | 1 | 2014 | 285 | 0.100 |
Why?
| | Haploinsufficiency | 1 | 2011 | 14 | 0.100 |
Why?
| | Chromosome Deletion | 2 | 2013 | 140 | 0.100 |
Why?
| | Mosaicism | 1 | 2011 | 18 | 0.100 |
Why?
| | Genotyping Techniques | 1 | 2011 | 20 | 0.100 |
Why?
| | Blotting, Northern | 1 | 2011 | 109 | 0.100 |
Why?
| | RNA, Small Interfering | 2 | 2008 | 215 | 0.090 |
Why?
| | Genome-Wide Association Study | 1 | 2011 | 166 | 0.090 |
Why?
| | Neoplastic Stem Cells | 2 | 2022 | 103 | 0.090 |
Why?
| | Typhoid Fever | 1 | 2010 | 2 | 0.090 |
Why?
| | Salmonella typhi | 1 | 2010 | 3 | 0.090 |
Why?
| | Case-Control Studies | 2 | 2017 | 1126 | 0.090 |
Why?
| | Middle Aged | 6 | 2020 | 12206 | 0.090 |
Why?
| | Viremia | 1 | 2010 | 22 | 0.090 |
Why?
| | Bacterial Typing Techniques | 1 | 2010 | 39 | 0.090 |
Why?
| | Daunorubicin | 2 | 2022 | 12 | 0.090 |
Why?
| | WT1 Proteins | 1 | 2009 | 4 | 0.090 |
Why?
| | Antibodies, Viral | 1 | 2010 | 88 | 0.090 |
Why?
| | Cytarabine | 2 | 2022 | 39 | 0.090 |
Why?
| | DNA, Bacterial | 1 | 2010 | 188 | 0.090 |
Why?
| | Viral Nonstructural Proteins | 1 | 2010 | 56 | 0.090 |
Why?
| | Cohort Studies | 2 | 2016 | 1422 | 0.080 |
Why?
| | Prospective Studies | 3 | 2022 | 2379 | 0.080 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2008 | 19 | 0.080 |
Why?
| | Pedigree | 1 | 2008 | 125 | 0.080 |
Why?
| | Aged | 4 | 2022 | 9405 | 0.080 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 2009 | 154 | 0.080 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2007 | 15 | 0.070 |
Why?
| | Wilms Tumor | 1 | 2007 | 18 | 0.070 |
Why?
| | Genes, Tumor Suppressor | 1 | 2007 | 73 | 0.070 |
Why?
| | Severity of Illness Index | 2 | 2024 | 951 | 0.070 |
Why?
| | Amino Acid Sequence | 1 | 2008 | 586 | 0.070 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2007 | 95 | 0.070 |
Why?
| | Molecular Sequence Data | 1 | 2008 | 793 | 0.070 |
Why?
| | DNA Helicases | 1 | 2008 | 144 | 0.070 |
Why?
| | Mice | 4 | 2023 | 5759 | 0.070 |
Why?
| | Cell Differentiation | 2 | 2021 | 650 | 0.070 |
Why?
| | Models, Biological | 1 | 2009 | 723 | 0.070 |
Why?
| | Animals | 6 | 2023 | 13246 | 0.070 |
Why?
| | Kidney Neoplasms | 1 | 2007 | 176 | 0.070 |
Why?
| | Cell Line | 1 | 2008 | 1021 | 0.060 |
Why?
| | Tacrolimus | 1 | 2005 | 52 | 0.060 |
Why?
| | Graft vs Host Disease | 1 | 2005 | 75 | 0.060 |
Why?
| | Transcriptome | 2 | 2017 | 320 | 0.060 |
Why?
| | DNA | 1 | 2008 | 541 | 0.060 |
Why?
| | Follow-Up Studies | 2 | 2020 | 2190 | 0.060 |
Why?
| | Autoimmune Diseases | 1 | 2005 | 101 | 0.060 |
Why?
| | Nucleosome Assembly Protein 1 | 1 | 2024 | 1 | 0.060 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2024 | 17 | 0.060 |
Why?
| | Factor VIII | 1 | 2024 | 23 | 0.060 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2024 | 14 | 0.060 |
Why?
| | Proto-Oncogenes | 1 | 2024 | 27 | 0.060 |
Why?
| | DEAD-box RNA Helicases | 1 | 2024 | 34 | 0.060 |
Why?
| | Retinoblastoma-Binding Protein 2 | 1 | 2023 | 6 | 0.060 |
Why?
| | Nuclear Pore Complex Proteins | 1 | 2023 | 9 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2024 | 33 | 0.060 |
Why?
| | Autoantibodies | 1 | 2024 | 116 | 0.060 |
Why?
| | CpG Islands | 1 | 2023 | 107 | 0.050 |
Why?
| | Disease Management | 1 | 2024 | 176 | 0.050 |
Why?
| | Computational Biology | 1 | 2024 | 216 | 0.050 |
Why?
| | Apoptosis | 1 | 2008 | 1112 | 0.050 |
Why?
| | Hemorrhage | 1 | 2024 | 197 | 0.050 |
Why?
| | Vaccination | 1 | 2024 | 271 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-cbl | 1 | 2022 | 3 | 0.050 |
Why?
| | Core Binding Factor beta Subunit | 1 | 2021 | 3 | 0.050 |
Why?
| | Myosin Heavy Chains | 1 | 2021 | 20 | 0.050 |
Why?
| | RNA | 1 | 2022 | 171 | 0.050 |
Why?
| | Prevalence | 2 | 2018 | 951 | 0.050 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2021 | 33 | 0.050 |
Why?
| | Disease Models, Animal | 2 | 2021 | 1458 | 0.050 |
Why?
| | Acetylation | 1 | 2021 | 97 | 0.050 |
Why?
| | Enhancer Elements, Genetic | 1 | 2021 | 61 | 0.050 |
Why?
| | RNA-Binding Proteins | 1 | 2021 | 123 | 0.050 |
Why?
| | Trans-Activators | 1 | 2021 | 134 | 0.050 |
Why?
| | Genetic Association Studies | 1 | 2021 | 116 | 0.050 |
Why?
| | HEK293 Cells | 1 | 2021 | 224 | 0.040 |
Why?
| | Mice, Inbred BALB C | 1 | 2021 | 305 | 0.040 |
Why?
| | Receptors, GABA-A | 1 | 2019 | 12 | 0.040 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2021 | 179 | 0.040 |
Why?
| | Up-Regulation | 1 | 2021 | 453 | 0.040 |
Why?
| | Pandemics | 1 | 2024 | 562 | 0.040 |
Why?
| | Hematopoietic Stem Cells | 1 | 2021 | 184 | 0.040 |
Why?
| | Oxidative Stress | 1 | 2024 | 771 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2023 | 1416 | 0.040 |
Why?
| | Protein Binding | 1 | 2021 | 665 | 0.040 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2024 | 567 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2020 | 380 | 0.040 |
Why?
| | Histones | 1 | 2021 | 313 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 636 | 0.040 |
Why?
| | Pilot Projects | 1 | 2020 | 697 | 0.040 |
Why?
| | Etoposide | 1 | 2017 | 72 | 0.040 |
Why?
| | Erythroid Cells | 1 | 2017 | 5 | 0.040 |
Why?
| | Genes, Dominant | 1 | 2017 | 19 | 0.040 |
Why?
| | Erythropoiesis | 1 | 2017 | 16 | 0.040 |
Why?
| | Genes, X-Linked | 1 | 2017 | 7 | 0.040 |
Why?
| | Models, Genetic | 1 | 2017 | 170 | 0.030 |
Why?
| | Protein-Tyrosine Kinases | 1 | 1996 | 95 | 0.030 |
Why?
| | Basic Reproduction Number | 1 | 2015 | 1 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2017 | 475 | 0.030 |
Why?
| | Family Health | 1 | 2015 | 80 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2017 | 378 | 0.030 |
Why?
| | Methylation | 1 | 2014 | 123 | 0.030 |
Why?
| | Placebos | 1 | 2013 | 86 | 0.030 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2013 | 65 | 0.030 |
Why?
| | Immunomodulation | 1 | 2013 | 37 | 0.030 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2013 | 17 | 0.030 |
Why?
| | Treatment Failure | 1 | 2013 | 116 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2017 | 1581 | 0.030 |
Why?
| | Killer Cells, Natural | 1 | 2013 | 107 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 181 | 0.030 |
Why?
| | Models, Statistical | 1 | 2014 | 224 | 0.030 |
Why?
| | Retrospective Studies | 1 | 2024 | 6134 | 0.030 |
Why?
| | Age Factors | 1 | 2015 | 1092 | 0.020 |
Why?
| | Thalidomide | 1 | 2013 | 377 | 0.020 |
Why?
| | Cryptococcus gattii | 1 | 2010 | 1 | 0.020 |
Why?
| | Flucytosine | 1 | 2010 | 14 | 0.020 |
Why?
| | DNA Gyrase | 1 | 2010 | 4 | 0.020 |
Why?
| | Cytokines | 1 | 2013 | 613 | 0.020 |
Why?
| | Nepal | 1 | 2010 | 11 | 0.020 |
Why?
| | Risk Assessment | 1 | 2015 | 1262 | 0.020 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2010 | 18 | 0.020 |
Why?
| | Immunoassay | 1 | 2010 | 20 | 0.020 |
Why?
| | Algorithms | 1 | 2014 | 618 | 0.020 |
Why?
| | High-Throughput Screening Assays | 1 | 2010 | 36 | 0.020 |
Why?
| | Amphotericin B | 1 | 2010 | 110 | 0.020 |
Why?
| | Haplotypes | 1 | 2010 | 84 | 0.020 |
Why?
| | Drug Resistance, Bacterial | 1 | 2010 | 71 | 0.020 |
Why?
| | Point-of-Care Systems | 1 | 2010 | 56 | 0.020 |
Why?
| | RNA, Viral | 1 | 2010 | 126 | 0.020 |
Why?
| | Microbial Sensitivity Tests | 1 | 2010 | 270 | 0.020 |
Why?
| | Retroviridae | 1 | 2008 | 5 | 0.020 |
Why?
| | Anaerobiosis | 1 | 2008 | 18 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2009 | 454 | 0.020 |
Why?
| | Transduction, Genetic | 1 | 2008 | 45 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2008 | 106 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2010 | 863 | 0.020 |
Why?
| | Ankyrin Repeat | 1 | 2007 | 3 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2015 | 3154 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2007 | 71 | 0.020 |
Why?
| | Antifungal Agents | 1 | 2010 | 339 | 0.020 |
Why?
| | Survival Rate | 1 | 2009 | 901 | 0.020 |
Why?
| | Signal Transduction | 1 | 2014 | 1622 | 0.020 |
Why?
| | Bacterial Proteins | 1 | 2010 | 376 | 0.020 |
Why?
| | Fibroblasts | 1 | 2008 | 351 | 0.020 |
Why?
| | Absorption | 1 | 2005 | 21 | 0.020 |
Why?
| | Administration, Topical | 1 | 2005 | 56 | 0.020 |
Why?
| | Oxygen | 1 | 2008 | 325 | 0.020 |
Why?
| | Bone Marrow Transplantation | 1 | 2005 | 116 | 0.020 |
Why?
| | Skin Diseases | 1 | 2005 | 111 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2007 | 509 | 0.010 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2007 | 828 | 0.010 |
Why?
|
|
Farrar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|